NASHVILLE, Tenn., Nov. 1, 2023 /PRNewswire/ -- Brookdale Senior Living Inc. (NYSE: BKD) ("Brookdale" or the "Company") announced today that Lucinda "Cindy" Baier, President and Chief Executive Officer and Dawn Kussow, Executive Vice President & Chief Financial Officer will participate in the 2023 Stephens Annual Investment Conference on Wednesday, November 15, 2023.
The Brookdale fireside chat will begin at 9:00 am CST, and the live webcast can be accessed through the Company's website at brookdaleinvestors.com as well as by clicking here. A replay of the webcast will be available on the Company's website until January 31, 2024.
About Brookdale Senior Living
Brookdale Senior Living Inc. is the nation's premier operator of senior living communities. The Company is committed to its mission of enriching the lives of the people it serves with compassion, respect, excellence, and integrity. The Company, through its affiliates, operates independent living, assisted living, memory care, and continuing care retirement communities. Through its comprehensive network, Brookdale helps to provide seniors with care, connection, and services in an environment that feels like home. The Company's expertise in healthcare, hospitality, and real estate provides residents with opportunities to improve wellness, pursue passions, make new friends, and stay connected with loved ones. Brookdale, through its affiliates, operates and manages 672 communities in 41 states as of September 30, 2023, with the ability to serve more than 60,000 residents. Brookdale's stock trades on the New York Stock Exchange under the ticker symbol BKD. For more information, visit brookdale.com or connect with Brookdale on Facebook or YouTube.
Last Trade: | US$5.16 |
Daily Change: | 0.08 1.58 |
Daily Volume: | 245,757 |
Market Cap: | US$1.030B |
December 09, 2024 November 11, 2024 November 06, 2024 September 30, 2024 September 10, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB